Altimmune, Inc. Q2 2025 Earnings Recap

ALT Q2 2025 August 12, 2025

Get alerts when ALT reports next quarter

Altimmune reported positive second-quarter results, showcasing pembiguate's statistical success in NASH trial endpoints, reinforcing its potential pipeline and solidifying its financial position with $183.1 million in cash reserves.

Earnings Per Share Beat

$-0.27 vs $-0.32 est.

+15.6% surprise

Revenue Beat

5000 vs 1429 est.

+249.9% surprise

Market Reaction

1-Day +3.31%

5-Day +0.0%

30-Day +0.55%

See ALT alongside your other holdings

Add to your portfolio — free

Key Takeaways

Pembiguate achieved statistical significance in NASH resolution and key efficacy measures during the IMPACT trial's 24-week period.
The company has initiated Phase II trials for alcohol use disorder (AUD) and alcohol-associated liver diseases (ALD) with famidutide.
Jerry Durso has been appointed as Chairman, a strategic move to guide the transition to Phase III development for pembidutide.
Altimmune's impressive cash position enables continued advancement of clinical programs and strategic initiatives.
Pemvigutide demonstrated favorable safety and tolerability profiles, enhancing its competitiveness among NASH therapies.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit ALT on AllInvestView.

Next Q3 2025